When combined with selected contrast media, magnetic resonance imaging (MRI) is a valuable tool in the diagnosis and treatment monitoring of tumors in the liver, and other parts of the body. However, today’s MRI contrast media cannot be used for patients with severely impaired kidney function due to the risk of serious side effects. CMC Contrast has developed an effective and safe contrast medium, CMC-001, which increases the chance of detecting changes in the liver and thereby optimizes the treatment of patients with renal failure.
CMC-001 is the first contrast medium to have been assigned orphan drug status by the US Food and Drug Administration (FDA). The contrast medium is administered orally and is effectively absorbed by the liver cells, with minimal systematic exposure. Preparations for pivotal clinical phase III trials are currently ongoing.
CMC Contrast at a glance
What they do: Makes it possible for more patient groups to undergo safe MRI examinations
Founded in: 1999
Headquarters: Malmö, Sweden